AVASTIN

Manufacturer:

Genentech

Name:

AVASTIN

Category:

J Code

HCPCS:

J9035

NDC(s):

50242-0060-10, 50242-0061-01, 50242-0061-10, 50242-0060-01,

Primary Type:

Cancer

Route of Administration:

Intravenous

About:

AVASTIN is a Cancer drug manufactured by Genentech and administered via the Intravenous route of administration. The J Code: J9035 is aligned to the drug AVASTIN.

Avastin works in combination with certain chemotherapies to prevent tumor growth in various types of cancer. By blocking the growth of new blood vessels that cancer cells depend on, Avastin stop cancer cells from growing and reproducing. As of 2023, there are multiple biosimilar drugs available for Avastin including Mvasi (Q5107), Riabni (Q5123), and Zirabev (Q5118). Insurance coverage information for Avastin can be found at https://www.avastin.com/hcp/contact-a-representative.html. Additionally, Genentech patient financial assistance can be found here: https://www.avastin.com/patient/financial-resources.html.